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Abstract
Increases in aminotransferases levels are frequently encountered in HIV-positive patients and often remain
unexplained. The role in this setting and natural history of hepatitis E in HIV-infected patients are unknown. The
aim of the study was to assess HEV infection in HIV-infected patients attending a Parisian hospital, with a current
or previous cryptogenic hepatitis.191 plasma samples collected from 108 HIV-infected patients with elevated
aminotransferases levels were retrospectively tested for the presence of hepatitis E virus (HEV) infection markers:
anti-HEV IgM antibodies, anti-HEV IgG antibodies, anti-HEV IgG avidity index and plasma HEV RNA.One acute
infection, documented by positive tests for anti-HEV IgM antibody, low anti-HEV IgG avidity index and plasma HEV
RNA (genotype 3e), and three past infections were diagnosed, without any observed case of persistent infection.
The acute hepatitis was benign and resolved spontaneously within two weeks. This infection was probably
contracted locally. Acute HEV hepatitis can occur in HIV-infected patients but rarely explains cryptogenic hepatitis,
at least in an urban HIV population, regardless geographic origin and CD4 counts.
Findings
Hepatitis E virus (HEV) hepatitis is endemic in develop-
ing and emerging in industrialized countries [1], where
seroprevalence ranges from 1 to 20% [2]. HEV was
thought to cause acute hepatitis, but chronic hepatitis in
organ transplant recipients [3], and reactivation after
stem cell transplantation [4] have been reported. Few
acute infections [5,6] and a persistent carriage [7] in
HIV-positive patients have been published. As elevated
transaminase levels are frequent, often unexplained in
HIV-positive patients, we studied the role of HEV in
this setting.
From 1250 HIV-positive patients followed-up in the
Infectious Diseases Department, 108 with at least one
episode of elevated aminotransferase levels above twice
the upper limit of normal (ULN, 50 I.U./mL) between
January 2005 and December 2008 were included after
written consent was obtained. As hepatitis E can worsen
chronic liver disease [8], and be misdiagnosed with
drug-induced liver injury [9], HBsAg or HCV RNA-
positive patients, those with alcoholic or drug-induced
liver injury were not excluded.
Plasma was screened retrospectively for anti-HEV IgG
and IgM (EIAgen HEV IgG
®, EIAgen HEV IgM
®,A d a l -
tis, Bologna, Italy), based on synthetic immunodominant
determinants encoded by ORF2 (aa 619-660) and ORF3
(aa 101-123) derived from Burma virus and Mexican
strain. From 200 μl of plasma, HEV RNA was amplified,
using real-time RT-PCR able to amplify any HEV geno-
type with a limit detection test of 500 copies/ml [10].
An external inhibition control was tested for each sam-
p l et or u l eo u tp o s s i b l ei n h i b i t o r sw i t hc a l c i u mi o n s
containing in EDTA tubes used for collection of plasma.
For IgG positive samples, IgG avidity index was deter-
mined to differentiate recent (avidity index< 40%) from
past infection (avidity index> 40%), this test being pre-
viously validated [11].
From 108 included patients (M/F: 2.3, ages: 42.1 ±
8.6 years for males, 38.3 ± 9.5 years for females), two
hundred and twelve episodes of elevated transaminases
levels were recorded (1 to 8/patient), from which 191
plasma (1 to 8/patient) could be tested. CD4 count was
347 ± 225/mm
3 and HIV RNA load was 5.3 ± 6 log10/
mL at the onset of transaminasitis; 86/108 patients were
given antiretroviral therapy (ART), 18/108 (16.7%) were
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any medium, provided the original work is properly cited.Table 1 Demographic and biological characteristics of patients seropositive for HIV-1 with acute or past HEV infection
Patient N° Sex Age
(years)
ALT
(xULN)
AST
(xULN)
CD4 + T lymphocytes
absolute count/mm
3
Plasmatic HIV RNA
(log10 copies/mL)
Sample N° Time from onset of
transaminasitis
(months)
Anti HEV
IgM OD/CO
Anti HEV
IgG OD/CO
IgG avidity
index (%)
RNA
HEV
Conclusion
At onset of transaminasitis
1 M 34 1 1 1 - 1 0.5 0.6 NEG No HEV
infection
20 12 286 3.4 2 0 10.8 4.2 7.5 Acute HEV
1 1 3 +1 10.8 4.2 11 POS infection
1 1 4 +12 2.2 3.9 34
NEG
NEG
2 F 32 8 3 215 4.1 1 0 0.1 4.3 86 NEG Past
infection
3 M 57 2.5 2.5 223 5.1 1 0 0.2 7.2 73 NEG Past
infection
4 M 52 2 2.5 1 - 4 0.7 4.8 90 NEG Past
infection
4 3 246 3.0 2 0 0.9 5.4 88
1 1 3 + 12 0.7 7.1 93 NEG
1 1 4 + 18 0.6 7.0 100 NEG
NEG
OD/CO: Optical density/Cut Off; the results were considered as positive if OD/CO exceeded 1.
ULN: Upper Limit of Normal values, 50 I.U./mL. ALT: alanine aminotransferases. AST: aspartate aminotransferases.
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4HBV, 25/108 (23.1%) were HCV, 3/108 (2.8%) were
HBV-HCV-coinfected respectively.
Acute HEV infection was diagnosed in one patient
(Table, Patient 1). He was born in France, homosexual,
tested HIV-1 positive in 2006, with 340 CD4/mm
3 and
7,000 copies/mL. Prophylaxis with trimethoprim/sulfa-
methoxazole was begun in April 2008 (280 CD4/mm
3,
12%). In June, ART (tenofovir/emtricitabine + atazanavir/
ritonavir) was started; biological liver tests were normal.
Eight weeks later, alanine (ALT) and aspartate (AST)
aminotransferases reached respectively 20 ULN and 12
ULN, without any physical complaints. ART was with-
drawn, biological tests normalized within two weeks.
HEV RNA (genotype 3e, Genbank GU084155), anti-HEV
IgM and IgG (avidity index 10%) were present, confirm-
ing a recent infection. Hepatitis A, B, C acute infections
were excluded. HEV infection was self limiting, with no
persistent carriage. The original ART schedule was
resumed, without any episode of transaminasitis. Neither
HEV RNA nor anti-HEV antibodies were detected three
weeks prior to the onset of hepatitis, showing recent
exposure to HEV. The patient denied travel to endemic
regions but reported regular consumption of under-
cooked pork. His partner was tested negative for serologi-
cal and molecular HEV markers (Table 1).
Past HEV infection was diagnosed in three patients,
based on detection of IgG without IgM, and negative
RNA. The first case (Table, patient 2), born in Camer-
oon, had an acute episode of fever of unknown origin
with transaminasitis. She reported frequently eating
undercooked bush red meat (braised monkey, coypu,
wart hog, porcupine meat) in Cameroon. The second
case (Table, patient 3) was detected in a man born in
Yugoslavia. Increase of aminotransferases was related to
myocardial infarction. He mentioned eating under-
cooked pork meats coming from cattle farms in Yugo-
slavia during childhood. The third case (Table, patient
4) was reported in a patient born and living during his
childhood in Algeria. Chronic transaminasitis was attrib-
uted to HCV-coinfection.
Markers of HEV infection were detected in four (3.7%)
of the HIV-infected patients with elevated transaminase
levels. One acute indigenous infection was diagnosed,
with a favourable outcome, as in few previously reported
cases [5,6], whose CD4 were above 200/mm
3,c o n t r a s t -
ing with a persistent carriage in a HIV-infected patient
with CD4 below 200/mm
3 [7], and chronic HEV hepati-
tis in organ-transplant recipients [3] and patients with
leukaemia [4]. Avidity matur a t i o np r o c e s si sT - c e l l
dependent and CD4 are the lines of specific immune
response to HEV [12]. In our patient, IgG avidity index
remained low after one year, suggesting a low matura-
tion of immune response. Correspondingly, a defect in
specific antibody avidity in response to measles vaccina-
tion and to measles was reported in HIV-infected chil-
dren [13].
The source of indigenous hepatitis E infection in
industrialized countries is uncertain. In our case of
acute infection, the hypothesis of sexual transmission
from his partner can be discarded, as he was tested
negative for HEV.
In three patients with past infection, the exposure may
have been in their native countries, the date of contami-
nation could not be determined.
HEV was possibly transmitted in these four patients
via consumption of undercooked pork, but there is no
control group and no HEV RNA detection from the
potential source was possible in our study.
Epidemiologic studies of HEV hepatitis in HIV-
infected patients are scarce. In Buenos Aires, the sero-
prevalence (6.6%) was higher than in control groups
(1.8%), most of the patients being intravenous drug
users or homosexuals [14]. Recently, Madejon et al.
have investigated 50 HIV-infected patients with CD4 <
200 cells/mm
3 and 43 with cryptogenic hepatitis, and
did not found HEV viremia [15]. Renou et al. identified
three Caucasian patients with acute HEV infection from
a survey conducted in Southern France which screened
1 3 3p a t i e n t s[ 6 ] .A sw i t ht h et w op r e v i o u sr e p o r t s
[6,15], this present study, testing patients with elevated
transaminases, was not designed to estimate the preva-
lence of anti-HEV in the HIV-infected patients.
Testing 191 plasma samples in 108 patients with at least
one episode of elevated aminotransferase levels during four
consecutive years, we described a single case of indigenous
acute HEV hepatitis. Acute hepatitis can occur in HIV-
infected patients but rarely explains cryptogenic hepatitis,
at least in an urban population, regardless of geographic
origin and CD4 counts. Nevertheless, with the increased
number of indigenous Hepatitis E infection in France (a
total of 180 cases in 2009 in France at least (unpublished
data from CNR Hepatitis E virus)) the investigation of
HEV markers in HIV-infected patients with unexplained
elevated transaminases should be recommended.
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